Publication

Structural Basis of the Allosteric Inhibition of Human ABCG2 by Nanobodies

Related publications (49)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Structural Basis of the Allosteric Inhibition of Human ABCG2 by Nanobodies

Graph Chatbot

Chat with Graph Search

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Antibody-peptide conjugates for targeted inhibition of cysteine proteases

A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress–Induced Inflammation

Combination of dielectrophoretic and hydrodynamic traps for the controlled contact between cells or beads and application to adhesion assays

KRAB zinc finger proteins link heterochromatin maintenance to replicative stress and inflammation in diffuse large B-cell lymphoma

Assessment of metal-based dihydrofolate reductase inhibitors on a novel mesofluidic platform

Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism

Structural basis of drug recognition by the multidrug transporter ABCG2

Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth

Metabolic plasticity and glucose transporter redundancy dictate lung adenocarcinoma growth